Prof. Davies talks about the interrelationship between T2DM, CVD (including heart failure) and CKD and how treatment with GLP-1RAs affects these interrelated systems.
HFA Discoveries These analyses of patient-reported outcomes in EMPERIAL trials suggest a trend towards reductions in HF symptom burden with empagliflozin compared to placebo in HFrEF patients.
HFA Discoveries This analysis of the DAPA-HF trial showed that the benefits of dapagliflozin persisted irrespective of use of diuretics or diuretic dose.
Dr. Constanzo explains the function of SGLT2 in the early proximale tubule of the kidney in detail and discusses how blockade of SGLT2 may result in beneficial effects.
ADA 2020 The VERTIS-CV trial demonstrated CV safety with ertugliflozin, but no decrease in MACE was observed with ertugliflozin compared to placebo in T2DM patients with CVD.
Patients with diabetic kidney disease (DKD) have an unmet residual CV risk. Prof. Stroes brings up some novel opportunities to treat this risk and elaborates on mechanisms of CV benefit by GLP-1RAs.
ADA 2020 A prespecified analysis from REDUCE-IT demonstrated that first and total (first plus recurrent) CV events were reduced with icosapent ethyl compared to placebo in patients with diabetes.
ADA 2020 The ATP citrate lyase inhibitor bempedoic acid lowered LDL-c compared to placebo in high-risk CV patients across all glycemic status subgroups, shown by a pooled analysis from four phase 3 trials.
ADA 2020 The SGLT2 inhibitor dapagliflozin reduced risk of new-onset T2DM in HFrEF patients, demonstrated by a prespecified analysis of the DAPA-HF trial.
ERA-EDTA 2020 The initial eGFR dip after initiation of empagliflozin has raised some concerns. A post-hoc analysis was therefore performed to investigate the impact of an eGFR dip.
ERA-EDTA 2020 An analysis of pooled data from CVOT trials that evaluated semaglutide showed that semaglutide slowed down decline of eGFR compared to placebo.
Mark Cooper gives an overview of older glucose lowering therapies and more recent newer treatment options, with a focus on SGLT2 inhibitors, and their effect on kidney outcomes in CDK and DKD patients. With question